Hodgkin Lymphoma

P=N/A, N=108, Not yet recruiting, Centre Henri Becquerel

P3, N=360, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P1, N=45, Active, not recruiting, AstraZeneca | Phase classification: P1/2 --> P1

P2, N=125, Not yet recruiting, University of Washington

Fifty days post-admission, Mycobacterium bovis BCG was identified in the initial sputum cultures. Concomitant interstitial pneumonia and BCG infection should be considered in patients with abnormal chest imaging following intravesical BCG therapy.

Many genetic abnormalities, mainly associated with the TCR signaling pathway, are observed, and most are more frequent in the aggressive type than in the indolent type, except for STAT3, indicating the heterogeneous pathogenic process of ATLL. In this review, we present the latest findings on molecular pathogenesis and histopathological findings of ATLL in the era of the new classification of lymphomas, serving as a basis for future research and classification.

P=N/A, N=27, Completed, University of Erlangen-Nürnberg Medical School | Recruiting --> Completed | N=50 --> 27

In our case, ITK-related immune dysregulation and prior exposure to oncological treatments seem to have simultaneously intervened in the same individual, leading to the development of a unique clinical profile. It is essential to raise awareness of the two-way association between immune dysregulation disorders and multiple tumors.

The study highlights the long-term risk of BC in HL survivors and suggests that advanced RT techniques and targeted therapies may help reduce the incidence of secondary tumors. Future research should focus on understanding the genetic and biological mechanisms behind treatment-induced cancers.

By blocking this interaction, checkpoint inhibitors such as nivolumab and pembrolizumab have demonstrated high response rates in patients with cHL, particularly in those who have not responded to conventional therapies. By understanding how TNF signaling interacts with immune checkpoints, researchers can design more effective treatment regimens that simultaneously target multiple pathways. Combining TNF inhibitors with checkpoint blockade therapies may enhance the overall anti-tumor response by addressing both direct tumor signaling and the immune evasion mechanisms employed by tumor cells.

Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of survivors of Hodgkin lymphoma and hereditary consequences for their offspring. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell toxicity while maintaining similar clinical efficacy.

P=N/A, N=40, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Conclusion The occurrence of HL in terms of prevalence, age, gender, and stage in our study is similar to other Asian countries. Notable correlations were observed between HL subtypes with age and stage.

P3, N=123, Recruiting, BeiGene | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Sep 2024 --> Feb 2026

No abstract available

P1, N=50, Not yet recruiting, FBD Biologics Limited | Initiation date: Sep 2024 --> Jan 2025

P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Apr 2029 --> Nov 2029 | Trial primary completion date: Apr 2027 --> Nov 2027

Furthermore, increased activity of macrophages and reduced expression of B-cells support previous studies underlining their involvement in treatment resistance. Despite limitations in sample size, these findings shed light on the mechanisms behind resistance and early relapse in cHL, which could help guide the development of targeted therapies and potentially improve early risk assessment.

P2, N=22, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

P3, N=299, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Jun 2025 --> Jul 2024

P2, N=257, Recruiting, Memorial Sloan Kettering Cancer Center | N=69 --> 257

P3, N=900, Recruiting, Genmab | Trial primary completion date: Sep 2028 --> Jun 2027

High BID and low CD20 expression were associated with inferior overall survival, while high BID and low JAK3 and CD20 expression were linked to poorer progression-free survival. These findings highlight altered protein profiles in pretreatment cHL biopsies associated with BPT development.

P1, N=10, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2039 --> Jul 2037 | Trial primary completion date: Nov 2024 --> Apr 2025

Recent data on combining brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine demonstrated improved overall survival compared to ABVD but increased adverse events (AEs). Further evaluation of programmed death receptor 1 inhibitor and CD30 antibody-drug conjugate combination regimens in frontline advanced stage cHL is warranted. Trial registration: NCT03646123.

These findings demonstrate that amdizalisib is rapidly absorbed, extensively metabolized, and primarily excreted via feces and urine, supporting its continued development as a potential therapeutic for Hodgkin's lymphoma. https://www.chinadrugtrials.org.cn/, identifier CTR20212448.

P1, N=18, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=110 --> 18

Following incubation with nivolumab, the duration of contacts between CD4-positive T cells and CD30-positive Hodgkin-Reed-Sternberg cells was documented. The preliminary data indicate that 3D and 4D experiments in hematopathology may facilitate new insights into diagnostics, biology, and clinical applications, including the development of new lymphoma classifications.

Understanding these dynamics is essential for developing targeted interventions to prevent PTOA. Future research should focus on elucidating the specific roles of these immune cell populations in PTOA progression and exploring potential therapeutic strategies.

P1, N=42, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2025 --> Jan 2024

Autophagy is enhanced in children with HL and increases with disease stage. Ag85B can inhibit the proliferation and autophagy of HL tumor cells and promote apoptosis, possibly related to the activation of the PI3K/Akt/mTOR pathway.

P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025

Following successful surgical management and the simultaneous diagnosis of a pulmonary relapse from a prior thyroid carcinoma, the patient remains under clinical surveillance. This is particularly significant given the patient's history of multiple tumors, including Hodgkin's lymphoma, papillary thyroid carcinoma, prostate cancer, and SFT.

P1/2, N=39, Active, not recruiting, Umar Farooq | Trial primary completion date: Apr 2025 --> Aug 2024

P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027

This case presents a patient who developed KIN with a progressively rising serum creatinine after ifosfamide, carboplatin and brentuximab treatment. Although ifosfamide and carboplatin have known associations with the development of KIN, this case raises the possibility that brentuximab, which has a different mechanism of action, also may be associated with KIN. Additionally, the genetic findings demonstrate that drug-induced KIN can develop in the absence of FAN1 mutations, a finding not previously reported.

P1/2, N=240, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

In summary, our research over the past three decades identified cHL as the first lymphoid malignancy driven by a disturbed telomere/shelterin/lamin AC interaction, generating the diagnostic RS. Our findings may act as trailblazer for tailored therapies in refractory cHL.

P2, N=37, Recruiting, David Bond, MD | Trial primary completion date: Dec 2024 --> Dec 2025

Here, we review FoxO1's roles across B cell and myeloid malignancies, namely acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and multiple myeloma (MM). We also discuss preclinical evidence for FoxO1 targeting by currently available inhibitors (AS1708727, AS1842856, cpd10).

P1/2, N=23, Active, not recruiting, University of Pennsylvania | Trial primary completion date: Oct 2024 --> May 2024

P1/2, N=39, Active, not recruiting, Umar Farooq | Suspended --> Active, not recruiting